ATE265204T1 - Micropartikeln zur verwendung in nadellosen injektion - Google Patents

Micropartikeln zur verwendung in nadellosen injektion

Info

Publication number
ATE265204T1
ATE265204T1 AT99943130T AT99943130T ATE265204T1 AT E265204 T1 ATE265204 T1 AT E265204T1 AT 99943130 T AT99943130 T AT 99943130T AT 99943130 T AT99943130 T AT 99943130T AT E265204 T1 ATE265204 T1 AT E265204T1
Authority
AT
Austria
Prior art keywords
microparticles
needleless injection
therapeutic agent
agent
spray
Prior art date
Application number
AT99943130T
Other languages
English (en)
Inventor
Nicholas David Osborne
Original Assignee
Quadrant Drug Delivery Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10838317&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE265204(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Quadrant Drug Delivery Ltd filed Critical Quadrant Drug Delivery Ltd
Application granted granted Critical
Publication of ATE265204T1 publication Critical patent/ATE265204T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Glanulating (AREA)
  • Physical Or Chemical Processes And Apparatus (AREA)
  • Disintegrating Or Milling (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
AT99943130T 1998-09-03 1999-09-03 Micropartikeln zur verwendung in nadellosen injektion ATE265204T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9819272.7A GB9819272D0 (en) 1998-09-03 1998-09-03 Microparticles
PCT/GB1999/002930 WO2000013668A1 (en) 1998-09-03 1999-09-03 Microparticles

Publications (1)

Publication Number Publication Date
ATE265204T1 true ATE265204T1 (de) 2004-05-15

Family

ID=10838317

Family Applications (2)

Application Number Title Priority Date Filing Date
AT04075082T ATE386507T1 (de) 1998-09-03 1999-09-03 Mikropartikel
AT99943130T ATE265204T1 (de) 1998-09-03 1999-09-03 Micropartikeln zur verwendung in nadellosen injektion

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT04075082T ATE386507T1 (de) 1998-09-03 1999-09-03 Mikropartikel

Country Status (15)

Country Link
US (3) US20020197325A1 (de)
EP (2) EP1107737B1 (de)
JP (2) JP2002524411A (de)
CN (1) CN1315854A (de)
AT (2) ATE386507T1 (de)
AU (1) AU5640799A (de)
BR (1) BR9913456A (de)
CA (1) CA2342206C (de)
DE (2) DE69916856T2 (de)
DK (1) DK1107737T3 (de)
ES (2) ES2301929T3 (de)
GB (1) GB9819272D0 (de)
IL (1) IL141323A0 (de)
MX (1) MXPA01002323A (de)
WO (1) WO2000013668A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000053160A1 (en) * 1999-03-08 2000-09-14 Powderject Research Limited Delivery of microparticle formulations using needleless syringe device for sustained-release of bioactive compounds
US8771740B2 (en) * 1999-12-20 2014-07-08 Nicholas J. Kerkhof Process for producing nanoparticles by spray drying
DE10045521A1 (de) 2000-03-31 2001-10-04 Roche Diagnostics Gmbh Nukleinsäureamplifikationen
WO2002058670A1 (en) * 2001-01-25 2002-08-01 Euroceltique S.A. Local anesthetic, and method of use
EP1399132A1 (de) * 2001-06-08 2004-03-24 Powderject Vaccines, Inc. Herstellung von harten und dichten partikeln
DE60227691D1 (de) 2001-11-01 2008-08-28 Nektar Therapeutics Sprühtrocknungsverfahren
US9339459B2 (en) 2003-04-24 2016-05-17 Nektar Therapeutics Particulate materials
JP2007508240A (ja) * 2003-07-22 2007-04-05 バクスター・インターナショナル・インコーポレイテッド 低分子量有機分子の小球状粒子ならびにその調製方法および使用方法
JP4210231B2 (ja) * 2004-03-25 2009-01-14 株式会社資生堂 皮膚のシワを改善する美容方法及びシワ改善具
US8728525B2 (en) 2004-05-12 2014-05-20 Baxter International Inc. Protein microspheres retaining pharmacokinetic and pharmacodynamic properties
AU2006228535A1 (en) * 2005-03-31 2006-10-05 Rafael Armament Development Authority Ltd. Apparatus for treating particles and liquids by ultrasound
JP5243247B2 (ja) * 2005-07-28 2013-07-24 アイエスピー インヴェストメンツ インコーポレイテッド スプレー乾燥された粉体及び粒状化された材料の特性の改良方法、並びにそれによって製造した製品
EP1976486A1 (de) * 2006-01-27 2008-10-08 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin Verfahren zur herstellung von porösen mikroteilchen
MX2009001226A (es) 2006-08-04 2009-03-20 Baxter Int Composicion basada en microesferas para prevenir y/o revertir la diabetes autoinmune de nuevo inicio.
DE202006018609U1 (de) * 2006-08-29 2007-05-16 Euro-Celtique S.A. Verwendung von Opioidformulierungen in nadellosen Vorrichtungen zur Medikamentenverabreichung
US20080085315A1 (en) * 2006-10-10 2008-04-10 John Alfred Doney Amorphous ezetimibe and the production thereof
WO2008076780A2 (en) * 2006-12-14 2008-06-26 Isp Investments Inc. Amorphous valsartan and the production thereof
US8613946B2 (en) * 2006-12-21 2013-12-24 Isp Investment Inc. Carotenoids of enhanced bioavailability
EP2125938A2 (de) * 2007-01-26 2009-12-02 Isp Investments Inc. Verfahren zur herstellung einer formulierung für sprühgetrocknete produkte
ITMI20080807A1 (it) 2008-05-05 2009-11-06 Antibioticos Spa Procedimento per la preparazione di tigeciclina in forma amorfa
US8367427B2 (en) 2008-08-20 2013-02-05 Baxter International Inc. Methods of processing compositions containing microparticles
US8323685B2 (en) 2008-08-20 2012-12-04 Baxter International Inc. Methods of processing compositions containing microparticles
US8323615B2 (en) 2008-08-20 2012-12-04 Baxter International Inc. Methods of processing multi-phasic dispersions
CN101732259B (zh) * 2009-12-29 2012-08-29 广东药学院 壳聚糖微米粒及其制备方法和应用
US9135998B2 (en) * 2010-11-09 2015-09-15 Micron Technology, Inc. Sense operation flags in a memory device
EP2898894A1 (de) 2014-01-27 2015-07-29 LTS LOHMANN Therapie-Systeme AG Nano-in-mikro-Teilchen zur intradermalen Verabreichung
JP7054954B2 (ja) * 2018-01-10 2022-04-15 ジー２ジーバイオ インコーポレイテッド コラーゲンペプチドを含有したポリカプロラクトン微粒球フィラーおよびその製造方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3937668A (en) * 1970-07-15 1976-02-10 Ilse Zolle Method for incorporating substances into protein microspheres
CA1077842A (en) * 1975-10-09 1980-05-20 Minnesota Mining And Manufacturing Company Albumin medicament carrier system
US4247406A (en) * 1979-04-23 1981-01-27 Widder Kenneth J Intravascularly-administrable, magnetically-localizable biodegradable carrier
US4349530A (en) * 1980-12-11 1982-09-14 The Ohio State University Implants, microbeads, microcapsules, preparation thereof and method of administering a biologically-active substance to an animal
US4357254A (en) * 1981-01-12 1982-11-02 Chemical Sciences, Inc. Cleaning composition
FR2505657A1 (fr) * 1981-05-13 1982-11-19 Pasteur Institut Perfectionnements apportes aux agents de stabilisation de virus vivants pour la preparation de vaccins, et vaccins stabilises contenant lesdits agents de stabilisation
US5707644A (en) * 1989-11-04 1998-01-13 Danbiosyst Uk Limited Small particle compositions for intranasal drug delivery
FR2663224B1 (fr) * 1990-06-14 1995-01-20 Applicationes Farmaceuticas Sa Forme galenique parenterale.
DE69313865T2 (de) * 1992-10-16 1998-02-12 Glaxo Group Ltd Geschmacksmaskierende zusammensetzungen von ranitidin
TW404844B (en) * 1993-04-08 2000-09-11 Oxford Biosciences Ltd Needleless syringe
US5899880A (en) * 1994-04-08 1999-05-04 Powderject Research Limited Needleless syringe using supersonic gas flow for particle delivery
NZ288185A (en) * 1994-06-15 1998-02-26 Dumex Alpharma As Particulate pharmaceutical formulation containing coated cores comprising at least 80% of an inert carrier having a friability of <20%; the inert carrier can be calcium carbonate
IT1274879B (it) * 1994-08-03 1997-07-25 Saitec Srl Apparecchio e metodo per preparare forme farmaceutiche solide a rilascio controllato del principio attivo.
GB9502879D0 (en) * 1995-02-14 1995-04-05 Oxford Biosciences Ltd Particle delivery
KR100201352B1 (ko) * 1995-03-16 1999-06-15 성재갑 단일주사 백신 제형
US5922253A (en) * 1995-05-18 1999-07-13 Alkermes Controlled Therapeutics, Inc. Production scale method of forming microparticles
US6117449A (en) * 1996-03-22 2000-09-12 Bio-Sphere Technology, Inc. Method for inducing a systemic immune response to a hepatitis antigen
US5985309A (en) * 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
GB9612629D0 (en) * 1996-06-17 1996-08-21 Oxford Biosciences Ltd Method for providing dense particle compositions for use in transdermal particle delivery

Also Published As

Publication number Publication date
DE69916856T2 (de) 2005-04-21
ES2301929T3 (es) 2008-07-01
AU5640799A (en) 2000-03-27
JP2002524411A (ja) 2002-08-06
BR9913456A (pt) 2001-07-24
JP2006096755A (ja) 2006-04-13
EP1107737A1 (de) 2001-06-20
DE69938201T2 (de) 2009-02-12
MXPA01002323A (es) 2002-05-08
EP1410792B1 (de) 2008-02-20
CN1315854A (zh) 2001-10-03
ES2223181T3 (es) 2005-02-16
US20050002870A1 (en) 2005-01-06
US20070026081A1 (en) 2007-02-01
EP1410792A8 (de) 2004-12-29
US20020197325A1 (en) 2002-12-26
IL141323A0 (en) 2002-03-10
CA2342206C (en) 2006-12-12
EP1107737B1 (de) 2004-04-28
ATE386507T1 (de) 2008-03-15
DK1107737T3 (da) 2004-08-02
GB9819272D0 (en) 1998-10-28
CA2342206A1 (en) 2000-03-16
DE69938201D1 (de) 2008-04-03
WO2000013668A1 (en) 2000-03-16
DE69916856D1 (de) 2004-06-03
EP1410792A1 (de) 2004-04-21

Similar Documents

Publication Publication Date Title
ATE265204T1 (de) Micropartikeln zur verwendung in nadellosen injektion
DE69836514D1 (de) Elektrodenkörper, mit diesem versehener Akkumulator, sowie Herstellung des Elektrodenkörpers und des Akkumulators
GR3025596T3 (en) Compositions and methods for identifying biologically active molecules.
WO1999014346A3 (en) SENSE mRNA THERAPY
CY1107351T1 (el) Καινοφανης μεταλλαγμενη μορφη απιμινασης αργινινης
NZ505408A (en) Magnetically responsive composition, comprising ferrocarbon and a biologically active substance
BR9910251A (pt) Estimulação hematopoiética
DE60117615D1 (de) Arzneimittelkombinationen (z.b. chlorpromazin und pentamidin) zur therapie von neoplastischen erkrankungen
TR200102308T2 (tr) Yüzey etkinliğine sahip yapay peptidler ve bunların yapay yüzey aktif maddelerin hazırlanmasında kullanımı
MX9603925A (es) Combinaciones de anticoagulantes y proteinas activas tromboliticamente, y usos de las mismas.
ATE280496T1 (de) Verfahren zur behandlung von asthma mit o- desulfatisiertem heparin
DE69113386D1 (de) Herstellung von Medikamenten zur Behandlung von Asthma, unter Verwendung von (S)-Alpha-Fluoromethyl-Histidin und dessen Estern.
NO961291D0 (no) Prosess II
ATE230618T1 (de) Fibrin-gewebekleber-formulierung und verfahren zu dessen herstellung
EP1123414A4 (de) Antisense modulation der expression von integrin alpha 4
NO971341L (no) Promoter for reseptor tyrosinkinase TIE
BG102623A (en) New derivatives of benzoylguanadine, methods for their preparation and application for the manufacture of medicamentous forms
GEP20043267B (en) Adenosine Receptor Antagonists, Methods of Making and Using the Same
IT1295751B1 (it) Procedimento per la produzione di protesi dentali fisse in resina, inserti per le stesse e protesi fisse cosi&#39; ottenute
DE69821498D1 (de) Verwendung von amifostin
ATE433461T1 (de) Rana pipiens proteine und deren verwendung in der behandlung von tumoren
WO1998040498A3 (en) Immunoadhesins and methods of production and use thereof
ATE271852T1 (de) Verbesserte inhalationspräparate
BR0000698A (pt) 15, 15&#39;-dioxigenases de beta, beta-caroteno
BG105204A (en) Salts of paroxetine

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1107737

Country of ref document: EP